Minakem
Building blocks, intermediates and Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
€14.5m | Late VC | ||
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (12 %) | 18 % | (9 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (17 %) | (45 %) | (2 %) | (33 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Minakem, a subsidiary of the Minafin Group, is a contract development and manufacturing organization (CDMO) that serves the pharmaceutical industry. The company specializes in the production of active pharmaceutical ingredients (APIs) and highly potent active pharmaceutical ingredients (HPAPIs), from laboratory-scale development to full industrial-scale manufacturing.
Its business model is centered around providing customized services to pharmaceutical companies, supporting them throughout their drug development lifecycle. This includes process development, analytical services, quality control, and regulatory support for filings with authorities like the FDA. Minakem operates several cGMP (current Good Manufacturing Practices) certified sites in Europe and the US, enabling it to serve a global client base ranging from small biotech startups to large pharmaceutical corporations. The company generates revenue by charging for its development services and for the commercial manufacturing of APIs.
Keywords: CDMO, active pharmaceutical ingredients, API manufacturing, pharmaceutical industry, process development, highly potent APIs, custom synthesis, cGMP manufacturing, chemical development, contract manufacturing